10May 2023
Randomized phase II clinical trial of ruxolitinib plus simvastatin in COVID19 clinical outcome and cytokine evolution

Randomized phase II clinical trial of ruxolitinib plus simvastatin in COVID19 clinical outcome and cytokine evolution

The study aimed to determine if the combination of ruxolitinib and simvastatin could reduce the incidence of respiratory insufficiency in COVID-19 patients with mild disease. The study found that the treatment did not impact the outcome of COVID-19. However, cytokine profiling identified patients at risk of severe disease and predicted clinical deterioration with 85% accuracy. The study suggests that managing the inflammatory response to SARS-CoV-2 could prevent respiratory insufficiency and that cytokine profiles could be useful in identifying cases at risk of severe disease.

  • #family health

Like

Save

Share